What is the current Cell Therapy Manufacturing market size?

The Cell Therapy Manufacturing market size is approximately USD 1.2 billion as of 2023.

What are the key drivers of the Cell Therapy Manufacturing market?

Key drivers include rising incidence of chronic diseases and growing investment in cell therapy research.

What are the major challenges facing the Cell Therapy Manufacturing market?

Challenges include high production costs, regulatory hurdles, and scalability issues.

Which regions are leading the Cell Therapy Manufacturing market?

North America and Europe are currently leading, due to strong healthcare infrastructure.

Who are the top companies in the Cell Therapy Manufacturing market?

Top companies include Novartis, Gilead Sciences, and Celgene, driving innovation and growth.

What future opportunities exist in the Cell Therapy Manufacturing market?

Future opportunities include emerging markets, new technologies, and increasing adoption of cell therapies.

How is technology impacting the Cell Therapy Manufacturing market?

Advances in technology are improving manufacturing efficiency, reducing costs, and enhancing product quality.

What is the current regulatory landscape for the Cell Therapy Manufacturing market?

The regulatory landscape is evolving, with ongoing updates to guidelines and standards for cell therapy manufacturing.

What is the future outlook for the Cell Therapy Manufacturing market?

The future outlook is promising, with expected growth driven by increasing demand and innovation.

What Is the Global Cell Therapy Manufacturing Market Worth in 2026?

Cell Therapy Manufacturing by Application (Clinical, Commercial, Pre-clinical), by Types (Autologous, Allogenic), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Cell Therapy Manufacturing Market Size | CAGR 15.2 Forecast 2033

What Is the Global Cell Therapy Manufacturing Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cell Therapy Manufacturing Market Overview

The Cell Therapy Manufacturing market refers to the industry involved in the production of cell therapies, which are medical treatments that use living cells to replace or repair damaged tissues. As the cell therapy manufacturing market size is expected to reach $12.8 billion by 2026, the growth outlook and market forecast indicate a promising industry expansion. The scope of this market encompasses various types of cell therapies, including autologous and allogenic cell therapies, and immunotherapies.

Loading chart…

The current Cell Therapy Manufacturing market size is approximately $6.8 billion, with a growth forecast indicating a compound annual growth rate (CAGR) of 14.5% during the forecast period from 2026 to 2033. Key forces shaping the industry include technology shifts, such as the adoption of automated manufacturing systems, regulations, such as the increasing scrutiny of cell therapy manufacturing processes, and competitive intensity, driven by the entry of new players in the market. The largest region in the Cell Therapy Manufacturing market is North America, while the fastest-growing region is Asia-Pacific. These trends and factors will drive the industry expansion and shape the market outlook for the Cell Therapy Manufacturing market in the coming years.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Avantor; Cell Therapies; Thermo Fisher Scientific; Charles River Laboratories; Catalent; Bio-Techne; Cytiva; Lonza; BIOCENTRIQ; FUJIFILM Diosynth Biotechnologies; Novartis; Bristol-Myers Squibb; Gilead; WuXi AppTec; Pharmaron; Aldevron; Exothera
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cell Therapy Manufacturing market is poised for significant growth, driven by increasing demand for cell therapies and advancements in manufacturing technologies. The global Cell Therapy Manufacturing market size is expected to expand rapidly, with a growth forecast that underscores the potential for innovation and investment in this space.

Growth Drivers2 items

Advances in cell therapy research and development, including the discovery of new cell types and therapies, are driving growth in the Cell Therapy Manufacturing market

Government initiatives and funding for cell therapy research, as well as the establishment of regulatory frameworks, are supporting the expansion of the Cell Therapy Manufacturing market size

Restraints2 items

High production costs and the need for specialized facilities and equipment are limiting the growth of the Cell Therapy Manufacturing market, making it challenging for new entrants to compete

Stringent regulatory requirements and the need for standardized manufacturing processes are also constraining the growth forecast for the Cell Therapy Manufacturing market

Opportunities2 items

The increasing adoption of cell therapies in emerging markets is creating new opportunities for growth and expansion in the Cell Therapy Manufacturing market

The development of new technologies, such as automated manufacturing systems and advanced cell culture methods, is expected to improve efficiency and reduce costs in the Cell Therapy Manufacturing market

Challenges2 items

Ensuring the quality and consistency of cell therapy products is a significant challenge in the Cell Therapy Manufacturing market, requiring robust quality control and assurance systems

Managing the supply chain and logistics of cell therapy manufacturing, including the transportation and storage of sensitive cell materials, is a complex challenge that requires specialized expertise and infrastructure

Market Segmentation

Loading chart…

The Cell Therapy Manufacturing segmentation by application is a crucial aspect of the market, as it defines the areas where cell therapies are being utilized. The applications of cell therapy manufacturing can be broadly categorized into oncology, cardiovascular diseases, neurological disorders, and other diseases. Each of these applications contributes to the overall Cell Therapy Manufacturing market size, with oncology being the largest contributor due to the high prevalence of cancer and the increasing adoption of immunotherapies.

In terms of types, the Cell Therapy Manufacturing market can be segmented into allogenic and autologous cell therapies. Allogenic cell therapies involve the use of cells from a donor, whereas autologous cell therapies use cells from the patient themselves. The choice between these two types depends on the specific application and the desired outcome. Understanding the market taxonomy of Cell Therapy Manufacturing is essential to identify the areas of growth and opportunity in this rapidly evolving field.

Cell Therapy Manufacturing Segmentation Breakdown7 items

Application

Clinical

Commercial

Pre-clinical

Types

Autologous

Allogenic

Regional Insights

Loading chart…

The Cell Therapy Manufacturing market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of cell therapies, favorable policies, and significant investments in the region's infrastructure and ecosystem maturity.

Key drivers for each region include: North America - strong demographics, established infrastructure, and high adoption rates; Europe - favorable policies, significant investments, and a mature ecosystem; Asia Pacific - growing demand, increasing investments, and improving infrastructure; Latin America - rising demand, favorable policies, and expanding infrastructure; and Middle East & Africa - growing demand, increasing investments, and developing infrastructure.

The regional forecast indicates a positive outlook for the Cell Therapy Manufacturing market, with each region contributing to the overall market growth. Understanding the unique drivers and factors influencing each region is crucial for stakeholders to capitalize on emerging opportunities and navigate the competitive landscape.

Competitive Landscape

The Cell Therapy Manufacturing competitive landscape is moderately consolidated, with a mix of global players and local companies vying for market share. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are driving growth, but local companies are also gaining traction through strategic partnerships and regional expansion. The market is characterized by high competition, with companies focusing on differentiation through technology, service models, and channel strength.

Companies are adopting various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To mitigate these risks, companies are focusing on competitive differentiation through technology, service models, and cost advantages. Some notable strategies include regional expansion, vertical integration, and innovation pipeline development. The following companies are making strategic moves:

Merck: regional expansion

Avantor: vertical integration

Cell Therapies: innovation pipeline

Thermo Fisher Scientific: premium pricing

Charles River Laboratories: OEM tie-ups

Catalent: local manufacturing

Key Cell Therapy Manufacturing Companies18 items

Merck

Avantor

Cell Therapies

Thermo Fisher Scientific

Charles River Laboratories

Catalent

Bio-Techne

Cytiva

Lonza

BIOCENTRIQ

FUJIFILM Diosynth Biotechnologies

Novartis

Bristol-Myers Squibb

Gilead

WuXi AppTec

Pharmaron

Aldevron

Exothera

Market Ecosystem

The Cell Therapy Manufacturing ecosystem spans upstream, midstream, and downstream activities, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured as these entities interact to design, develop, and deliver cell therapies to patients. The ecosystem boundaries are defined by the flow of materials, services, and information from raw material suppliers to end users, with various participants playing critical roles in the value chain analysis.

Raw material suppliers — providing cell lines and reagents

Technology providers — developing cell processing and manufacturing technologies

OEMs / manufacturers — producing equipment and software for cell therapy manufacturing

System integrators / EPCs — designing and implementing manufacturing facilities

Distributors / channel partners — delivering cell therapies to healthcare providers

Service providers / after-sales — offering maintenance, support, and training services

Regulators/standards bodies — establishing guidelines and overseeing compliance

In the Cell Therapy Manufacturing ecosystem, control points are influenced by regulators, technology providers, and end users, who drive adoption and demand for cell therapies. Dependency risks arise from input constraints, such as limited availability of raw materials, and standards and approvals from regulatory bodies. Switching costs and partnerships between participants can also impact the ecosystem, with regional differences in regulations, healthcare systems, and patient needs affecting the flow of value and the interactions among participants.

Recent Industry Insights

The Cell Therapy Manufacturing industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and contract manufacturing organizations, have driven innovation and expanded production capacities. Notable mergers and acquisitions have also taken place, enabling companies to enhance their capabilities and strengthen their market presence. Furthermore, several product and technology launches have been observed, focusing on improving manufacturing efficiency, scalability, and compliance with regulatory requirements.

Additionally, regulatory changes have been implemented to ensure the quality and safety of cell therapies, while funding rounds and expansions have provided companies with the necessary resources to advance their research and development efforts. A notable shift in consumer and enterprise trends has also been observed, with a growing emphasis on personalized medicine and targeted therapies. These developments are expected to continue shaping the Cell Therapy Manufacturing industry trends, driving growth and innovation in the sector.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Cell Therapy Manufacturing market outlook. The market exhibits high attractiveness due to its growing demand and increasing investments in research and development. The competitive intensity is moderate, with key players focusing on innovation and strategic partnerships. The long-term outlook is positive, driven by the rising prevalence of chronic diseases and the need for effective treatments.

The innovation landscape is rapidly evolving, with advancements in cell culture technologies and gene editing tools. However, the demand-supply balance is a concern, with capacity constraints and regulatory hurdles affecting the market. Key risk factors include scalability issues and quality control concerns. Overall, the Cell Therapy Manufacturing market outlook is promising, with opportunities for growth and investment in this dynamic and rapidly evolving field.

11 items

1. Executive Summary

2. Cell Therapy Manufacturing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cell Therapy Manufacturing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cell Therapy Manufacturing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Clinical

6.1.2. Commercial

6.1.3. Pre-clinical

6.2. Global Cell Therapy Manufacturing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Autologous

6.2.2. Allogenic

6.3. Global Cell Therapy Manufacturing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cell Therapy Manufacturing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cell Therapy Manufacturing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cell Therapy Manufacturing Market Competition by Key Manufacturers

8.1. Global Cell Therapy Manufacturing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cell Therapy Manufacturing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Avantor

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Cell Therapies

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Charles River Laboratories

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Catalent

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bio-Techne

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Cytiva

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Lonza

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. BIOCENTRIQ

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. FUJIFILM Diosynth Biotechnologies

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Novartis

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Bristol-Myers Squibb

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Gilead

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. WuXi AppTec

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Pharmaron

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Aldevron

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Exothera

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cell Therapy Manufacturing Market

Figure 4: Global Cell Therapy Manufacturing Market: Drivers

Figure 5: Global Cell Therapy Manufacturing Market: Challenges

Figure 6: Global Cell Therapy Manufacturing Market: Trends

Figure 7: Global Cell Therapy Manufacturing Market: Opportunity

Figure 8: Global Cell Therapy Manufacturing Market: Restraint

Figure 9: Global Cell Therapy Manufacturing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cell Therapy Manufacturing Market Value (USD Million) By Region

Figure 15: Global Cell Therapy Manufacturing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cell Therapy Manufacturing Market Value (USD Million) By Region

Figure 23: Global Cell Therapy Manufacturing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Cell Therapy Manufacturing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cell Therapy Manufacturing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cell Therapy Manufacturing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cell Therapy Manufacturing Market Value (USD Million) By Region

Table 10: Global Cell Therapy Manufacturing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cell Therapy Manufacturing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cell Therapy Manufacturing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cell Therapy Manufacturing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck Basic Information And Sales Area

Table 31: Merck. Products Portfolio

Table 32: Avantor Basic Information And Sales Area

Table 33: Avantor. Products Portfolio

Table 34: Cell Therapies Basic Information And Sales Area

Table 35: Cell Therapies. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: Charles River Laboratories Basic Information And Sales Area

Table 39: Charles River Laboratories. Products Portfolio

Table 40: Catalent Basic Information And Sales Area

Table 41: Catalent. Products Portfolio

Table 42: Bio-Techne Basic Information And Sales Area

Table 43: Bio-Techne. Products Portfolio

Table 44: Cytiva Basic Information And Sales Area

Table 45: Cytiva. Products Portfolio

Table 46: Lonza Basic Information And Sales Area

Table 47: Lonza. Products Portfolio

Table 48: BIOCENTRIQ Basic Information And Sales Area

Table 49: BIOCENTRIQ. Products Portfolio

Table 50: FUJIFILM Diosynth Biotechnologies Basic Information And Sales Area

Table 51: FUJIFILM Diosynth Biotechnologies. Products Portfolio

Table 52: Novartis Basic Information And Sales Area

Table 53: Novartis. Products Portfolio

Table 54: Bristol-Myers Squibb Basic Information And Sales Area

Table 55: Bristol-Myers Squibb. Products Portfolio

Table 56: Gilead Basic Information And Sales Area

Table 57: Gilead. Products Portfolio

Table 58: WuXi AppTec Basic Information And Sales Area

Table 59: WuXi AppTec. Products Portfolio

Table 60: Pharmaron Basic Information And Sales Area

Table 61: Pharmaron. Products Portfolio

Table 62: Aldevron Basic Information And Sales Area

Table 63: Aldevron. Products Portfolio

Table 64: Exothera Basic Information And Sales Area

Table 65: Exothera. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global Cell Therapy Manufacturing Market Value (USD Million) By Region

Table 71: Global Cell Therapy Manufacturing Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: North America Market Value (USD Million) (2025-2032) By Types

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cell Therapy Manufacturing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Avantor; Cell Therapies; Thermo Fisher Scientific; Charles River Laboratories; Catalent; Bio-Techne; Cytiva; Lonza; BIOCENTRIQ; FUJIFILM Diosynth Biotechnologies; Novartis; Bristol-Myers Squibb; Gilead; WuXi AppTec; Pharmaron; Aldevron; Exothera
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options